Momelotinib (Ojjaara) for MF with anemia
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-MOMELOTINIB |
|---|
| ID | REG-MOMELOTINIB-PMF |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-MOMENTUM-VERSTOVSEK-2023 SRC-NCCN-MPN-2025 |
Notes
JAK1/JAK2 + ACVR1 inhibitor — distinguishes from ruxolitinib by improving anemia (ACVR1 → reduced hepcidin → restored erythropoiesis) where ruxolitinib often worsens anemia. MOMENTUM phase-3 vs danazol in JAKi-experienced anemic MF: symptom response 25% vs 9%, spleen response 22% vs 3%, TI 31% vs 20%. STUB — pending Co-Lead sign-off.
Used By
Indication
IND-PMF-MOMELOTINIB-ANEMIA- IND-PMF-MOMELOTINIB-ANEMIA